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Abstract Hantaviruses have previously been recognised to
cause two separate syndromes: hemorrhagic fever with
renal syndrome in Eurasia, and hantavirus pulmonary
syndrome (HPS) in the Americas. However, increasing
evidence suggests that this dichotomy is no longer fruitful
when recognising human hantavirus disease and under-
standing the pathogenesis. Herein are presented three cases
of severe European Puumala hantavirus infection that meet
the HPS case definition. The clinical and pathological
findings were similar to those found in American hantavi-
rus patients. Consequently, hantavirus infection should be
considered as a cause of acute respiratory distress in all
endemic areas worldwide.
Introduction
The present paradigm is that hantaviruses in the Americas
cause hantavirus pulmonary syndrome (HPS), while hemor-
rhagic fever with renal syndrome (HFRS) is caused by
hantaviruses present in Eurasia [1–3]. Hantaviruses associated
with HFRS and HPS are primarily transmitted by inhalation
of viral particles shed by infected rodents [4, 5]. In both
syndromes there is a local immune reaction in the lungs,
mainly in terms of a CD8
+ T lymphocyte response [2, 6, 7].
Another important feature is endothelial dysfunction and
capillary leakage [1–3, 8]. After the prodromal phase,
including fever, nausea, myalgia and headache, patients with
HFRS commonly develop renal failure whereas in HPS the
kidneys are often spared and instead the patient frequently
presents with severe cardiopulmonary dysfunction [1, 3, 9].
Although usually less severe and sometimes overlooked,
pulmonarysymptomsare commoninEuropeanHFRScaused
by Puumala virus (PUUV). Frequent clinical findings include
cough, dyspnoea, interstitial lung infiltrates, pleural effusion
and impaired pulmonary function [10–12]. Pronounced lung
involvement in HFRS has previously been reported [13–16].
However, none of those reported patients had a fatal
outcome that could be attributed to the acute infection, and
there is no description of histopathological findings.
Our hypothesis is that also European hantaviruses can cause
HPS. The aim of this study was to investigate whether HFRS
patients with severe cardiopulmonary distress fulfil HPS
criteria and have similar clinical and pathological features.
Materials and methods
In a prospective study, during the latest hantavirus outbreak
in 2007 in the county of Västerbotten, Sweden [17], HFRS
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were selected. We identified three patients, two of which had
fatal outcome and one survived. The two patients who died
both underwent autopsy three days post-mortem. Organ
samples were investigated using immunohistochemistry to
describe the immunological response and detect presence of
viral antigen. Quantitative real-time RT-PCR was used to
detect viral RNA in organ samples, plasma and bronchoal-
veolar lavage [18].
For defining HPS we used the case definition criteria
published by the U.S. Centers for Disease Control and
Prevention (CDC) [19]. The project was approved by the
Research Ethics Committee of Umeå University. Informed
consent was obtained either from the patient, or a close
relative when not possible.
Results
Patient 1
A 73-year-old woman was admitted to the intensive care
unit (ICU) with acute respiratory distress. She was a
lifelong non-smoker living with her husband in a rural
area, and had a medical history of hypertension and type II
diabetes. The day prior to admission she fell ill with
malaise and fever. Nausea, vomiting and pronounced
shortness of breath ensued. The initial findings at admission
included fever, tachycardia, tachypnoea, hypoxia and
somnolence. Laboratory findings during hospitalisation
indicated coagulopathy, elevated levels of lactate dehydro-
genase (LDH), and development of renal failure (Table 1).
There was release of cardiac enzyme troponin T (peak
value 1.6; normal value <0.01 μg/L), indicating myocardial
tissue damage.
Lung computer tomography (CT) on admission revealed
pronounced diffuse bilateral interstitial infiltrates with
pulmonary oedema, dependant atelectasis, and moderate
pleural effusions (Fig. 1) which were later drained
(>800 ml). Echocardiography showed inferior hypokinesia,
moderate mitral valve insufficiency, normal sized left
ventricle and atrium, and systolic pulmonary arterial
pressure estimated at 55 mm Hg. Despite non-invasive
positive pressure respiratory support and furosemide, her
respiratory distress progressed and she was intubated and
mechanically ventilated on the first hospital day. The
preliminary diagnosis was acute respiratory distress
syndrome of uncertain cause, and she was treated with
broad-spectrum antibiotics and corticosteroids without
improvement. Vasopressor and inotropic support was
required to maintain adequate circulation. Repeated
echocardiogram showed no overt signs of cardiac failure,
though several days into her illness the systolic pulmo-
nary arterial pressure increased to >65 mm Hg. Maximal
inspiratory pressures (40 cm H2O) were required to
maintain minimally adequate oxygenation. She suffered a
pneumothorax, and received a large bore thoracostomy
with negative pressure drainage. The patient developed
multiple organ dysfunction engaging the central nervous,
respiratory, cardiovascular, renal and coagulatory systems,
and she died after 13 days of ICU care.
PUUV serology was initially negative, but seroconver-
sion occurred during the first week with development of
positive immunoglobulin M (IgM) and IgG. No PUUV
RNA could be detected in serum or bronchoalveolar lavage
fluid, sampled two days after onset of disease. At autopsy
PUUV RNA was detected in lung tissue, but not in samples
from heart, brain, spleen and liver. Sequencing of the
PUUV RNA from lung tissue showed that it was
homologous to PUUV strains circulating in northern
Sweden. No PUUV antigen could be detected in the tissue
by immunohistochemistry using PUUV specific monoclo-
nal antibody. Relevant bacterial cultures were all negative.
Notably, three weeks prior to ICU admission the patient had
sought medical treatment at our clinic for a urinary tract
infection caused by E. coli. In the serum collected at that
time PUUV RNA (1,700 copies/ml) was later detected.
Table 1 Laboratory findings in three European hantavirus patients suffering from hantavirus pulmonary syndrome
Patient No., Sex/Age WBC
a TPC
b aPTT
a INR
a Albumin
b Creatinine
a LDH
a
1: F/73 y 6.5/40.9 293/42 26.7/40.9 1.2/1.9 29/28 50/234 11.4/30.8
2: F/65 y 15.5/50.3 108/17 49.9/>180.0 1.4/1.9 18/18 87/171 5.2/8.7
3: M/63 y 12.4/23.0 137/9 42.0/80.0 1.5/2.0 ND 124/164 21.2/21.2
WBC white blood cell count (normal range 3.5–8.8×10
9 /L), TPC thrombocyte particle count (normal range for women 165–387 and for men 145–
348×10
9 /L), aPTT activated partial thromboplastin time (normal range 24.0–36.0 seconds), INR international normalized ratio (normal range 0.8–1.2),
serum albumin (normal range 36–45 g/L), serum creatinine (normal range for women 50–90 and for men 60–100 μmol/L), LDH lactate dehydrogenase
(normal value <3.4 μkat/L), ND no data
aInitial and peak laboratory results, respectively
bInitial and nadir laboratory results, respectively
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no normal aerated tissue. Pulmonary histopathological
features consisted of diffusely oedematous parenchyma
with interstitial and intraalveolar fibrosis. The alveoli
contained exudates of fibrinous fluid, high number of
alveolar macrophages (CD68
+), proliferative epithelial
cells and thick septa but without characteristic hyaline
membranes. Interstitial mononuclear cell infiltrates were
common, consisting mainly of CD3
+ T lymphocytes
whereof a vast majority was CD8
+. Many mononuclear
cells were expressing cytotoxic markers granzyme B and
T cell restricted intracellular antigen-1, TIA-1 (Fig. 2). In
pulmonary vessels, focal thrombosis was evident. Micros-
copy of the heart showed thrombosis in small vessels and
focal massive infiltrates of granulocytes and macrophages.
In the brain there was focal vasculitis, perivascular
infiltration of CD8
+ T lymphocytes and non-occlusive
thrombosis. Infarctions were seen in the brain, lungs and
spleen. Notably, the kidneys had no prominent inflamma-
tory infiltrates.
Patient 2
A 65-year-old woman was admitted to the ICU with acute
respiratory distress and circulation insufficiency. Besides a
history of Waldenstrom’s macroglobulinemia that had not
required active treatment, she had no history of health
problems, infections or recent hospitalisations. She was a
lifelong non-smoker, lived in a rural home with her
husband, and handled firewood for home heating. Four
days prior to admission the patient noted fever, chills,
dyspnoea with dry cough and diarrhoea. On the day of
admission, these symptoms were more severe, and an
ambulance had been called because of syncope. Her ability
to oxygenate deteriorated progressively during the first
hospital day, and she was intubated and mechanically
ventilated.
Chest X-ray on admission showed bilateral diffuse
lung infiltrates and signs of interstitial oedema. Large
bilateral pleural effusions were noted, and >1000 ml
were drained. Echocardiographic examination identified
normal left ventricular wall motion, and no signs of
structural abnormalities or of pulmonary hypertension.
Thin-cut CT images of the lungs on the third ICU day
showed diffuse bilateral alveolar and interstitial infiltrates
with dependent consolidation (Fig. 1). The clinical course
during the first seven days was dominated by respiratory
insufficiency requiring maximal ventilatory support with
high levels of inspired oxygen, as well as circulatory
shock requiring treatment with vasopressor and inotropic
infusions. Other important clinical aspects included coa-
gulopathy with diffusely spread petechiae, progression of
renal failure with anuria requiring dialysis, and elevated
levels of LDH (Table 1). She was treated presumptively
for bacterial pneumonia and sepsis with a series of broad
spectrum antibiotics and corticosteroids, without apparent
response.
Hantavirus infection was verified with the detection of
PUUV RNA in plasma (630,000 copies/ml) on the day of
admission, while IgM and IgG were negative. Serocon-
version with positive IgM and IgG occurred two and
seven days later, respectively. Consecutive plasma sam-
ples were analysed for PUUV RNA with declining viral
copy numbers until negative 16 days post onset of
Fig. 1 Chest CT-scans of two European patients with hantavirus
pulmonary syndrome. The examination showed pronounced diffuse
bilateral interstitial infiltrates with pulmonary oedema, together with
bilateral dependent atelectasis and moderate pleural effusions in
patient 1 (a) and diffuse bilateral alveolar and interstitial infiltrates
with dependent consolidation in patient 2 (b)
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cases of hantavirus pulmonary syndrome. The findings were con-
densed oedematous pulmonary parenchyma with alveolar fibrinous
exudate and infiltrates of mononuclear cells (a), whereof a vast
majority were CD8
+ T lymphocytes (b), and many were holding
granules containing granzyme B (c) and T cell restricted antigen-1,
TIA-1 (d); this immunophenotype is characteristic of activated
cytotoxic T lymphocytes. In contrast, CD4
+ helper T lymphocytes
(e) were uncommon. Viral antigen was detected in capillary vascular
endothelium (f) and in mononuclear cells, here represented by a
monocyte (f; inset), using Puumala hantavirus nucleocapsid protein
monoclonal antibody (A1C5, Progen Biotechnik GmbH, Heidelberg,
Germany). For viral antigen, lung samples from two non-hantavirus
patients were used as negative controls (data not shown). Panels
(Patient 1 in a–e; original magnification, x 400; and Patient 3 in f;
original magnification, x 600) display lung sections from paraffin
embedded material. Staining was performed using hematoxylin and
eosin (a), and immunoperoxidase technique (b–f)
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bronchoalveolar lavage fluid (11,000 copies/ml) nine days
afteronsetofdisease.Bacterialcultureswereallnegative.The
patient remained ventilator-dependent for 13 days, but was
finallyextubated.Shedevelopedcriticalillnessmyopathyand
needed six weeks in-hospital rehabilitation. At follow-up six
months later, she complained of muscle ache during exercise
and lowered general fitness, but was steadily improving.
Patient 3
A 63-year-old male construction worker was admitted to
the ICU with acute respiratory distress, confusion and
hypotension. He was a current and long-time smoker
with a medical history of mild chronic obstructive
pulmonary disease and hypertension. Three days prior
to admission he had fallen ill with fever, chills,
diarrhoea, dry cough, and dyspnoea. In the emergency
room, physical examination was notable for fever,
somnolence, tachycardia and hypotension. Arterial blood
gas analysis on room air revealed hypoxia and respira-
tory alkalosis. The patient was taken to the ICU and
therapy was started with broad spectrum antibiotics due
to suspicion of pneumonia and sepsis. As with the other
patients, coagulopathy, increased LDH levels, and renal
f a i l u r ew e r ed e t e c t e d( T a b l e1).
Initial bedside chest X-ray showed no findings to
explain the respiratory distress. During the two days ICU
course, the patient complained mostly of dyspnoea. He
received supplemental oxygen and non-invasive ventila-
tor support initially, but was eventually intubated and
mechanically ventilated. CT findings which included
only the lower lung lobes revealed bilateral pleural
effusions and bibasilar atelectasis (data not shown).
During the first day blood pressure was maintained with
i.v. fluid, but on the second day his circulatory condition
rapidly deteriorated. Despite massive efforts with i.v.
fluid, corticosteroids and vasoactive drugs, the patient
died in refractory circulatory shock.
PUUV serology on the first hospital day was IgM
positive, while IgG was negative. The patient had 130,000
copies of PUUV RNA/ml in plasma. Bacterial cultures
were all negative. At autopsy, PUUV RNA was detected in
samples from lungs, heart, liver, kidney, brain and spleen.
The organs were examined for viral antigen, which was
found in the vascular endothelium and in mononuclear cells
(Fig. 2).
Post mortem examination showed that pulmonary
architecture was preserved but with oedema and focal
non-occlusive thrombosis. Similar to patient 1, there were
pulmonary infiltrates of lymphocytes with the same
immunophenotype as described (data not shown). Kidneys
showed no prominent inflammation.
Discussion
Growing evidence show that there are similarities between
HFRS and HPS, as both syndromes can give rise to
hemorrhagia, renal impairment and cardiopulmonary dys-
function, which have been attributed to thrombocytopenia
and capillary leakage [1, 3, 8, 9, 11, 20, 21].
Severe pulmonary involvement has not been generally
perceived to be a significant feature of HFRS. Previously,
respiratory symptoms were commonly attributed to fluid
overload as a result of renal failure. However, increasing
evidence show that lung and heart involvement is common
during the acute phase of HFRS [10, 11, 22, 23]. Concerning
the cases of European hantavirus infection in our present
report, there was only mild or no renal impairment at the time
of admission, whereas the respiratory involvement was early
and severe, consistent with acute respiratory distress syndrome
(ARDS), fulfilling criteria of HPS according to CDC case
definition [19]. As described in HPS, the three reported
patients suffered from cardiovascular dysfunction, requiring
treatment with inotropic and vasopressor drugs [9]. Autopsy
results support the cause of death to be cardiopulmonary
distress due to hantavirus infection. The lungs of both the
deceased patients were oedematous and contained mononu-
clear cell infiltrates with predominantly CD8
+ T lymphocytes,
as described in HPS patients [2, 7]. Many cells expressed
granzyme B and TIA-1, indicating a cytotoxic activity, which
c o u l df u r t h e rb es u p p o r t e db yh i g hl e v e l so fL D H .W ec h o s e
to demonstrate the immune response in a non-smoker’s lungs
(patient 1), but a similar picture was seen in patient 3.
In the first two patients, the IgM response was delayed,
while the quantitative real-time RT-PCR for PUUV RNA
was positive, suggesting it as a valuable tool to hasten the
aetiological diagnosis [18]. Notably, in patient 1 PUUV
RNA was found in serum from three weeks prior to the
acute onset of disease, that is, in incubation phase and
consistent with hantavirus incubation time ranging from
one to four weeks [3, 24].
Pulmonary involvement is well documented in European
Puumala hantavirus infection. From a single outbreak in
our county, we report on three cases of life-threatening
hantavirus pulmonary syndrome. Arguably, additional cases
are likely to either go undiagnosed or unreported. A clinical
implication of this observation is that hantavirus infection
should be included as a differential diagnosis for patients
with febrile illness and acute respiratory distress of
uncertain cause in endemic areas in Eurasia.
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